

Orchard Therapeutics (Europe) Limited
Proposed HTA licensing number 12754

Application for a licence under the Human Tissue Act 2004

Activities applied to be licensed

Area	Storage of relevant material which has come from a human body for use for a scheduled purpose	Removal from the body of a deceased person (otherwise than in the course of an anatomical examination or post-mortem examination) of relevant material of which the body consists or which it contains, for use for a scheduled purpose other than transplantation
Orchard Therapeutics (Europe) Limited	Applied to be licensed	Not applied to be licensed

Summary of visit findings

The HTA found the proposed Designated Individual (DI) and the proposed Licence Holder (LH) to be suitable in accordance with the requirements of the legislation.

Orchard Therapeutics (Europe) Limited ('the establishment') was found to have met all HTA standards.

The HTA has assessed the establishment as suitable to be licensed for the activities specified.

Compliance with HTA standards

All applicable HTA standards have been assessed as fully met.

Advice

The HTA advises the proposed DI to consider the following to further improve practices:

Number	Standard	Advice
1.	GQ1(a)	The establishment's HTA Quality Manual differentiates between material for research and GxP material. The proposed DI is advised to clarify this differentiation in establishment documents as GxP material may also be considered relevant material.
2.	GQ1(a)	Shipments are received at the building loading dock and then handed over to establishment staff. This process is not documented. To strengthen end-to-end traceability of the material, the proposed DI is advised to document the process for the initial receipt from couriers at the loading dock.
3.	T1(c)	The proposed DI is advised to implement a process for recording any limitations on storage and use of cells, and to record the end date of any approvals from recognised REC (rREC) approved studies. This will provide an assurance that stored cells are transferred to the governance of the HTA licence when rREC approval ends.
4.	PFE2(c)	The proposed DI is advised to include additional details in the SOP 'Maintenance and Monitoring of Cold Storage Equipment' on the procedures for challenging temperature alarms and responding to alarms out of hours. This will ensure that the SOP reflects the process described during the site visit.
5.	PFE2(c)	The laboratory manager reviews temperature graphs to detect any changes over time. The proposed DI is advised to consider implementing a documented procedure for trending temperatures as it may provide advance notice of a potential failure of the storage units.

Background

Orchard Therapeutics (Europe) Limited has applied for an HTA licence to store relevant material which has come from a human body for use for scheduled purposes. Relevant material will be purchased from commercial providers and will be stored in -80°C freezers, in vapour phase Liquid Nitrogen (LN2) dewars, or in 4°C laboratory fridges. In addition, cells may also be received from volunteers under rREC approval and may be transferred to the governance of the HTA licence when the rREC approval ends.

Description of activities undertaken during visit

The HTA's regulatory requirements are set out in Appendix 1. The Regulation Manager covered the following areas during the visit:

Standards assessed against during visit

There are 47 standards in the Research sector, of which 38 were assessed. Standards C1(a), C1(b), C1(d), C1(e), C1(f), C2(a), C2(b), C2(c), and PFE2(b) could not be assessed as the establishment does not intend to directly seek consent, or to store material from the deceased (standards published 3 April 2017).

Review of governance documentation

The assessment included a review of documentation relevant to the establishment's proposed licensable activities. This included policies and procedural documents, risk assessments, arrangements for temperature monitoring for the storage units, and a review of the commercially available cloud-based system that will be used to record and track relevant material.

Visual inspection

The visit included a visual inspection of the areas where the establishment proposes to undertake the licensable activity. This included the areas where relevant material will be received into the establishment and areas where samples will be stored.

Meetings with establishment staff

The visit included meetings and discussions with the proposed Designated Individual (DI), proposed Persons Designated, and other staff who will be working under the licence. This included the Laboratory and Facilities Manager, a Principle Investigator and a Senior Scientist.

Report sent to proposed DI for factual accuracy: 3 April 2023

Report returned from proposed DI: No factual accuracy or request for redaction comments were made by the DI

Final report issued: 5 April 2023

Appendix 1: The HTA's regulatory requirements

Prior to the grant of a licence, the HTA must assure itself that the DI is a suitable person to supervise the activity authorised by the licence and that the premises are suitable for the activity.

The statutory duties of the DI are set down in Section 18 of the Human Tissue Act 2004. They are to secure that:

- the other persons to whom the licence applies are suitable persons to participate in the carrying-on of the licensed activity;
- suitable practices are used in the course of carrying on that activity, and;
- the conditions of the licence are complied with.

Its programme of site visit inspections to assess compliance with HTA licensing standards is one of the assurance mechanisms used by the HTA.

The HTA developed its licensing standards with input from its stakeholders. They are designed to ensure the safe and ethical use of human tissue and the dignified and respectful treatment of the deceased. They are grouped under four headings:

- consent;
- governance and quality systems;
- traceability, and;
- premises facilities and equipment.

This is an exception-based report: only those standards that have been assessed as not met are included. Where the HTA determines that there has been a shortfall against a standard, the level of the shortfall is classified as 'Critical', 'Major' or 'Minor' (see Appendix 2: Classification of the level of shortfall). Where HTA standards are fully met, but the HTA has identified an area of practice that could be further improved, advice is provided.

HTA inspection reports are published on the HTA's website.

Appendix 2: Classification of the level of shortfall

Where the HTA determines that a licensing standard is not met, the improvements required will be stated and the level of the shortfall will be classified as 'Critical', 'Major' or 'Minor'. Where the HTA is not presented with evidence that an establishment meets the requirements of an expected standard, it works on the premise that a lack of evidence indicates a shortfall.

The action an establishment will be required to make following the identification of a shortfall is based on the HTA's assessment of risk of harm and/or a breach of the Human Tissue Act 2004 (HT Act) or associated Directions.

1. Critical shortfall:

A shortfall which poses a significant risk to human safety and/or dignity or is a breach of the HT Act or associated Directions

or

A combination of several major shortfalls, none of which is critical on its own, but which together could constitute a critical shortfall and should be explained and reported as such.

A critical shortfall may result in one or more of the following:

- A notice of proposal being issued to revoke the licence;
- Some or all of the licensable activity at the establishment ceasing with immediate effect until a corrective action plan is developed, agreed by the HTA and implemented;
- A notice of suspension of licensable activities;
- Additional conditions being proposed, or;
- Directions being issued requiring specific action to be taken straightaway.

2. Major shortfall:

A non-critical shortfall that:

- poses a risk to human safety and/or dignity, or;
- indicates a failure to carry out satisfactory procedures, or;
- indicates a breach of the relevant Codes of Practice, the HT Act and other relevant professional and statutory guidelines, or;

- has the potential to become a critical shortfall unless addressed.

or

A combination of several minor shortfalls, none of which is major on its own, but which, together, could constitute a major shortfall and should be explained and reported as such.

In response to a major shortfall, an establishment is expected to implement corrective and preventative actions within 1-2 months of the issue of the final inspection report. Major shortfalls pose a higher level of risk and therefore a shorter deadline is given, compared to minor shortfalls, to ensure the level of risk is reduced in an appropriate timeframe.

3. Minor shortfall:

A shortfall which cannot be classified as either critical or major, but which indicates a departure from expected standards.

This category of shortfall requires the development of a corrective action plan, the results of which will usually be assessed by the HTA either by desk based review or at the time of the next site visit.

In response to a minor shortfall, an establishment is expected to implement corrective and preventative actions within 3-4 months of the issue of the final inspection report.

Follow up actions

A template corrective and preventative action plan will be sent as a separate Word document with the final inspection report. Establishments must complete this template and return it to the HTA within 14 days of the issue of the final report.

Based on the level of the shortfall, the HTA will consider the most suitable type of follow-up of the completion of the corrective and preventative action plan. This may include a combination of

- a follow-up site visit inspection;
- a request for information that shows completion of actions;
- monitoring of the action plan completion, or;
- follow up at next routine site visit inspection.

After an assessment of the proposed action plan establishments will be notified of the follow-up approach the HTA will take.